Fig. 1From: Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysisImprovement in 6MWT over 24 weeks following ambrisentan treatment (patients with connective tissue disease) (ITT population-LOCF): post-hoc analysis. 6MWT, 6-min walk test; ITT, intent-to-treat; LOCF, last observation carried forwardBack to article page